AffiliationDepartment of Endocrinology, Christie Hospital, Manchester, M20 4BX, UK.
MetadataShow full item record
AbstractAcromegaly, a condition due to growth hormone hypersecretion usually from a benign pituitary tumour, is associated with significant morbidity and mortality. Disease control leads to normalisation of life expectancy with a reduction in signs and symptoms. Treatment modalities include surgery, radiotherapy and medical management. Surgery is the primary treatment in most of the patients, with success rates of 61-91% reported for those with microadenomas who are operated on by a specialist pituitary surgeon; however, most patients have macroadenomas and, although benefiting from surgery, are not cured and require additional medical therapy. This review will focus on emerging concepts in the medical treatment of acromegaly.
CitationRecent developments in the therapy of acromegaly. 2006, 15 (3):251-6 Expert Opin Investig Drugs
JournalExpert Opinion on Investigational Drugs
- Somatostatin analogs as primary medical therapy for acromegaly.
- Authors: Danoff A, Kleinberg D
- Issue date: 2003 Apr
- Authors: Scacchi M, Cavagnini F
- Issue date: 2006
- Current status and future directions of pharmacological therapy for acromegaly.
- Authors: Mercado M, Espinosa E, Ramírez C
- Issue date: 2016 Sep
- Pure endoscopic transsphenoidal surgery for treatment of acromegaly: results of 67 cases treated in a pituitary center.
- Authors: Gondim JA, Almeida JP, de Albuquerque LA, Gomes E, Schops M, Ferraz T
- Issue date: 2010 Oct
- The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone (GH) secreting adenoma.
- Authors: Lissett CA, Peacey SR, Laing I, Tetlow L, Davis JR, Shalet SM
- Issue date: 1998 Nov